Claims for Patent: 11,878,022

Summary for Patent: 11,878,022

Title:	Hydrochlorothiazide compositions
Abstract:	Disclosed herein is a powder for oral suspension and a reconstituted product thereof comprising highly pure hydrochlorothiazide, which is useful for treating hypertension and edema.
Inventor(s):	Muthusamy Shanmugam, Subramaniam ARUNKUMAR
Assignee:	Novitium Pharma LLC
Application Number:	US18/053,197
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 11,878,022
Patent Claims:	1. A powder for oral suspension for oral administration, comprising about 3% w/w to about 5% w/w of hydrochlorothiazide; at least one thickening agent; and at least one pharmaceutically acceptable excipient; wherein the powder for oral suspension composition in 5 mL of water has a pH of from about 3.5 to about 5.5. 2. The powder of claim 1 comprising about 3.5% w/w to about 4.4% w/w of hydrochlorothiazide. 3. The powder of claim 1 comprising about 4.2% w/w of hydrochlorothiazide. 4. The powder of claim 1 having a water content of not more than about 0.8% w/w. 5. The powder of claim 1, wherein the at least one thickening agent is selected from hydrocolloid gum, cellulosic derivative, a polysaccharide, alginate, acrylic acid copolymer, polyvinylpyrrolidone, aluminium magnesium silicate, and a combination thereof. 6. The powder of claim 1, wherein the amount of the at least one thickening agent is in an amount of from about 0.4% w/w to about 5% w/w. 7. The powder of claim 1, wherein the at least one thickening agent comprises xanthan gum in an amount of from about 0.4% w/w to about 2.5% w/w. 8. The powder of claim 1, wherein the at least one pharmaceutically acceptable excipient comprises a preservative and a sweetener. 9. The powder of claim 1, wherein the at least one pharmaceutically acceptable excipient comprises a preservative selected from the group consisting of sodium benzoate, benzoic acid, potassium sorbate, paraben, methylparaben, ethylparaben, propylparaben, butylparaben, isobutylparaben, benzyl alcohol, boric acid, calcium acetate, bentonite, cetrimide, chlorhexidine, cetylpyridinium chloride, cresol, chlorbutanol, magnesium tri silicate, and a combination thereof. 10. The powder of claim 1, wherein the at least one pharmaceutically acceptable excipient comprises a preservative selected from the group consisting of sodium benzoate, benzoic acid, potassium sorbate, paraben, methylparaben, ethylparaben, propylparaben, butylparaben, isobutylparaben, benzyl alcohol, boric acid, calcium acetate, bentonite, cetrimide, chlorhexidine, cetylpyridinium chloride, cresol, chlorbutanol, magnesium trisilicate, and combination thereof in an amount of from about 0.01% w/w to about 5% w/w. 11. The powder of claim 1, wherein the at least one pharmaceutically acceptable excipient comprises a sweetener selected from the group consisting of sucralose, maltilol, liquid glucose, magnasweet 110, magnasweet 180, saccharin sodium, xylitol, sorbitan monoleate, sorbitol, sucrose, aspartame, acesulfame potassium, and a combination thereof. 12. The powder of claim 1, wherein the at least one pharmaceutically acceptable excipient comprises a sweetener selected from the group consisting of sucralose, maltilol, liquid glucose, magnasweet 110, magnasweet 180, saccharin sodium, xylitol, sorbitan monoleate, sorbitol, sucrose, aspartame, acesulfame potassium, and a combination thereof in an amount of from about 0.1% w/w to about 96% w/w. 13. The powder of claim 1, wherein the at least one pharmaceutically acceptable excipient comprises a sweetener selected from the group consisting of sucralose, sucrose, and a combination thereof in an amount of from about 90% w/w to about 96% w/w. 14. The powder of claim 1, wherein the at least one pharmaceutically acceptable excipient comprises a pH modifier selected from group consisting of citric acid, fumaric acid, tartaric acid, malic acid, sodium phosphate monobasic, potassium phosphate, maleic acid, lactic acid, hydrochloric acid, phosphoric acid, and a combination thereof. 15. The powder of claim 1, wherein the at least one pharmaceutically acceptable excipient comprises a pH modifier selected from group consisting of citric acid, fumaric acid, tartaric acid, malic acid, sodium phosphate monobasic, potassium phosphate, maleic acid, lactic acid, hydrochloric acid, phosphoric acid, and a combination thereof in an amount of from about w/w to about 1.2% w/w. 16. The powder of claim 1, having a salamide impurity content not more than 1.0% for at least about 6-months when stored at 25±2° C. and 60±5% relative humidity, 40° C. and 75% relative humidity and a salamide impurity content not more than 1.0% for at least about 6-months when stored at 25±2° C. and 60±5% relative humidity after reconstitution. 17. An oral liquid suspension comprising the powder of claim 1 and a pharmaceutically acceptable carrier comprising water. 18. The oral liquid suspension of claim 17 having a volume of from about 50 mL to about 150 mL. 19. A method of treating edema and hypertension comprising administering to a patient in need thereof a therapeutically effective amount of the oral liquid suspension of claim 17. 20. The method of claim 19, wherein administration of the oral liquid suspension to the human patient provides a geometric least squares mean for Cmax of from about 200 ng/mL to about 450 ng/mL, a geometric least squares mean for AUC0-∞ of from about 1800 ng•hr/mL to about 2900 ng•hr/mL, or a combination thereof.